Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827606 · ClinicalTrials.gov registry record · Phase 3
Atorvastatin Three Year Pediatric Study
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT00827606 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 272 participants.
The verdict
NCT00827606, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.
Interventions
- DRUG atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827606
The ClinicalTrials.gov registry entry for NCT00827606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which atorvastatin is the first listed.
NCT00827606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827606 about?
NCT00827606 is a clinical study titled "Atorvastatin Three Year Pediatric Study". The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.
What is the current status of trial NCT00827606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2009-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00827606?
The interventions under investigation include: atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00827606?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.